BMS to Acquire Forbius for its AVID200 to Expand its Footprints in Oncology and Fibrosis

Shots: Forbius will receive up front and milestones while BMS will acquire Forbius’s TGF-beta program, including the lead investigational asset, AVID200. The transaction is expected to be closed in Q4’20 Prior to closing, Forbius’ non-TGF-beta assets will be transferred to a newly formed private company, which will be retained by Forbius’ existing shareholders AVID200 is …

BMS to Acquire Forbius for its AVID200 to Expand its Footprints in Oncology and Fibrosis Read More »